Showing papers for search query "Case+Study"+"FDA"

     Search term "Case+Study"+"FDA"
     Title Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study
     Author ['AC Eifler', 'CS Thaxton']
     Venue Biomedical nanotechnology
     Year 2011
     Abstract The approval of drugs for human use by the US Food and Drug Administration (FDA) through the Center for Drug Evaluation and Research (CDER) is a time-consuming and expensive process, and approval rates are low (DiMasi et al., J Health Econ 22: 151–185
     Url https://link.springer.com/protocol/10.1007/978-1-61779-052-2_21


     Search term "Case+Study"+"FDA"
     Title Estimating the extent of reporting to FDA: a case study of statin‐associated rhabdomyolysis
     Author ['M McAdams', 'J Staffa', 'G Dal Pan']
     Venue … and drug safety
     Year 2008
     Abstract Purpose To estimate the extent of reporting to FDA through statin‐associated rhabdomyolysis data. Methods Data included incidence rates (IRs) of hospitalized rhabdomyolysis among statin users from a population‐based study, and comparable
     Url https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.1535


     Search term "Case+Study"+"FDA"
     Title Framing Regulatory Standards to Avoid Formal Adjudication: The FDA as a Case Study
     Author ['CC Ames', 'SC McCracken']
     Venue Calif. L. Rev.
     Year 1976
     Abstract Recently the Food and Drug Administration has taken aggressive action to reduce the burden of prolonged administrative hearings by initiating the use of summary judgment, by allocating the burden of proof to the drug manufacturers in drug efficacy hearings, and by
     Url https://heinonline.org/hol-cgi-bin/get_pdf.cgi?handle=hein.journals/calr64&section=12


     Search term "Case+Study"+"FDA"
     Title Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology
     Author ['J Paradise', 'AW Tisdale', 'RF Hall']
     Venue The Journal of Law …
     Year 2009
     Abstract This article evaluates the oversight of drugs and medical devices by the US Food and Drug Administration (FDA) using an integration of public policy, law, and bioethics approaches and employing multiple assessment criteria, including economic, social, safety, and
     Url https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1748-720X.2009.00434.x


     Search term "Case+Study"+"FDA"
     Title Flood damage estimate (quantity), using HEC-FDA model. Case study: the Neka river
     Author ['SA Mohammadi', 'M Nazariha', 'N Mehrdadi']
     Venue Procedia Engineering
     Year 2014
     Abstract The cost of damages due to flooding depends on several factors. However, several methods, using different approaches, can be used to estimate flood damages. In this study, the residential area of Neka river, in the East of Mazandaran province (north of Iran), is
     Url https://www.sciencedirect.com/science/article/pii/S1877705814001325


     Search term "Case+Study"+"FDA"
     Title … sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting …
     Author ['G Sarganas', 'HD Orzechowski', 'A Klimpel']
     Venue Neuro …
     Year 2012
     Abstract Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults. Its established first-line adjuvant treatment is radiotherapy in combination with temozolomide (TZM). Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing
     Url https://academic.oup.com/neuro-oncology/article-abstract/14/5/541/1079491


     Search term "Case+Study"+"FDA"
     Title Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin
     Author ['JL DiGiacinto', 'KM Chan‐Tack']
     Venue The Journal of …
     Year 2008
     Abstract One of the numerous regulatory functions of the Food and Drug Administration (FDA) is the evaluation of drug‐drug interactions and the determination of appropriate dose adjustments, if necessary, to ensure the safe and effective use of medications. The FDA considers several
     Url https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/0091270008315308


     Search term "Case+Study"+"FDA"
     Title The FDA, the BATF, and Liquor Labeling: A Case Study of Interagency Jurisdictional Conflict
     Author ['IP Cooper']
     Venue Food, Drug, Cosmetic Law Journal
     Year 1979
     Abstract IN TWENTIETH-CENTURY AMERICA, the many administra tive agencies are the primary machinery of government. Oc casionally, the gears scrape together—as when Congress invests two agencies with overlapping jurisdictions. This article will examine, chronologically
     Url https://www.jstor.org/stable/26658540


     Search term "Case+Study"+"FDA"
     Title A case study of personalized medicine
     Author ['SH Katsanis', 'G Javitt', 'K Hudson']
     Venue SCIENCE-NEW YORK THEN …
     Year 2008
     Abstract This is consistent with FDA's approach to some other diagnostic devices (such as mag- netic resonance imaging machines), where it has left  As described in this case study, this indirect approach has had no apparent effect on the availability of tests with questionable clinical
     Url https://www.researchgate.net/profile/Sara_Katsanis/publication/5464826_A_Case_Study_of_Personalized_Medicine/links/09e41507da4c453d8b000000/A-Case-Study-of-Personalized-Medicine.pdf


     Search term "Case+Study"+"FDA"
     Title Regulatory controls for direct-to-consumer genetic tests: a case study on how the FDA exercised its authority
     Author ['M Curnutte']
     Venue New Genetics and Society
     Year 2017
     Abstract In February 2015, 23andMe received clearance from the United States Food and Drug Administration (FDA) for a carrier status test for a gene linked to Bloom syndrome. This was the first FDA authorization to market a direct-to-consumer (DTC) genetic test. Then, in April
     Url https://www.tandfonline.com/doi/abs/10.1080/14636778.2017.1354690

